Bystolic Cliff Is Coming Sooner Than Namenda Cliff
A sort of "pay ($9M to Glenmark) for delay generics." Seemingly, Glenmark will be settled.
Still two more (Amerigen and Watson) to go.
By Zacks Equity Research | Zacks – 4 hours ago..
Forest Labs (FRX) and Glenmark Pharmaceuticals S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India, recently signed a collaboration agreement. The companies will work on the development of novel mPGES-1 inhibitors for the treatment of chronic inflammatory conditions, including pain.
Potential candidates have already been identified by Glenmark. Glenmark is conducting pre-clinical studies with these candidates prior to the initiation of human studies.
Glenmark will receive an upfront payment of $6 million from Forest Labs. Moreover, Forest Labs will pay $3 million to fund the next phase of work. Additional payments will be made by Forest Labs in fiscal 2014 to support the development program. Once phase I development is completed, Forest Labs has an exclusive option to acquire licensing rights to the program.